(1347–1375) Rheumatoid Arthritis – Treatment Poster II

Monday, October 27, 2025

10:30 AM - 12:30 PM Central Time

Location: Hall F1

CE: 0.00

Presentations:

10:30 AM - 12:30 PM Central Time

86-96% of Rheumatoid Arthritis (RA) Patients with RA Who Have 0 or 1 Swollen Joint or Tender Joint but Are Classified as Moderate/high on RA Indices Have 1-9 Comorbidities Recognized on a Multidimensional Health Assessment Questionnaire (MDHAQ)
Abstract Poster Presenter: Theodore Pincus, MD, FACR, MACR – Rush University Medical Center
10:30 AM - 12:30 PM Central Time

Achievement of Treatment Targets and Maintenance of Response with Upadacitinib in Patients with Moderate-to-severe Rheumatoid Arthritis in a Real-world Setting: Final 2-year Outcomes from the UPHOLD Study
Abstract Poster Presenter: Andrew Ostor, MD – Australian National University
10:30 AM - 12:30 PM Central Time

Are Glucocorticoids Associated with Worse Overall Survival Among Rheumatoid Arthritis Patients Treated with Immune Checkpoint Inhibitors? The Confounding Effect of Dexamethasone
Abstract Poster Presenter: Deanna Jannat-Khah, MPH, DrPH – Hospital For Special Surgery
10:30 AM - 12:30 PM Central Time

AZD1163, a Novel Bispecific Human Antibody Targeting PAD2/4 Enzymes Responsible for Generating Citrullinated Protein Auto-antigens in Rheumatoid Arthritis, Demonstrates Dose-dependent Inhibition of Systemic PAD Activity in Healthy Volunteers
Abstract Poster Presenter: Susanne Prothon, MSc – AstraZeneca
10:30 AM - 12:30 PM Central Time

Comparative Safety Outcomes of Tofacitinib Versus Upadacitinib in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
Abstract Poster Presenter: Maya Khasho, MD – University of central florida
10:30 AM - 12:30 PM Central Time

Cost Per Responder Analysis of Certolizumab Pegol Versus Adalimumab in Patients with Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective from Canada and Brazil
Abstract Poster Presenter: Remi Marty, PharmD – UCB
10:30 AM - 12:30 PM Central Time

Economic impact of early treatment and strict disease control in rheumatoid arthritis: a cost-minimization approach concerning biological therapy
Abstract Poster Presenter: Raianni Rúbia Pacheco Silva, DSc (she/her/hers) – Universidade de Brasília
10:30 AM - 12:30 PM Central Time

Effect of bDMARDs and tsDMARDS on diffuse interstitial lung disease associated with rheumatoid arthritis: systematic review and meta-analysis
Abstract Poster Presenter: Stéphane HILLIQUIN, n/a – Département de Rhumatologie, Hôpital Cochin, Assistance publique des Hôpitaux de Paris, Université Paris-Cité, Paris, France
10:30 AM - 12:30 PM Central Time

Effect of Ivarmacitinib on Joint Swelling and Tenderness in Patients with Moderate-to-severe Rheumatoid Arthritis: A Post-hoc Study of a Phase III Clinical Trial
Abstract Poster Presenter: Hongtao Jin, MD – The Second Hospital of Hebei Medical University
10:30 AM - 12:30 PM Central Time

Effect of JAK Inhibitors on Bone Mineral Density in Rheumatoid Arthritis Patients with Osteoporosis: A Comparative Study with Biologics
Abstract Poster Presenter: Sungwon Ko, MD – ASAN MEDICAL CENTER
10:30 AM - 12:30 PM Central Time

Efficacy Of Ayurvedic Treatment Versus Placebo, Each In Combination With Methotrexate In Early RA Over 20 Weeks: An Exploratory Randomized Control Trial
Abstract Poster Presenter: Venkatesh Srinivasa Pai, MBBS, MD,DM (he/him/his) – AIIMS RISHIKESH
10:30 AM - 12:30 PM Central Time

Efficacy of Telitacicept in the treatment of Connective tissue disease-associated interstitial lung disease: A Potential therapeutic option
Abstract Poster Presenter: Mingfang Sun, MD – Department of Rheumatology & Clinical Immunology, Daping Hospital & Research Institute of Surgery, Army Medical University
10:30 AM - 12:30 PM Central Time

Evaluating Causal Effects of Biologic and Targeted Synthetic Disease-modifying Anti-rheumatic Drugs Targets in Rheumatoid Arthritis Using Mendelian Randomisation
Abstract Poster Presenter: Mihye Kwon, MD, PhD (she/her/hers) – Konyang University Hospital
10:30 AM - 12:30 PM Central Time

Evaluation of the Clinical Outcome of Baricitinib in Patients with Rheumatoid Arthritis from Multi-center Collaborative Study in Japan: Sub-analysis for Difficult-to-treat RA.
Abstract Poster Presenter: NAOKI Kondo, MD, PhD – Division of Orthopedic Surgery, Niigata University Medical and Dental General Hospital
10:30 AM - 12:30 PM Central Time

Impact of SGLT2 Inhibitors and GLP-1 Agonists on RA Flares in Patients on DMARD Therapy: A Retrospective Study
Abstract Poster Presenter: Shreya Sakthivel, DO – Anne Arundel Medical Center
10:30 AM - 12:30 PM Central Time

Impact of Six-Month Monitoring Compared to Three-Month Monitoring of Labs for Methotrexate Toxicity
Abstract Poster Presenter: Spencer Simko, MD, MPH (he/him/his) – University of Texas Southwestern
10:30 AM - 12:30 PM Central Time

Initial Biologic Therapy Improves Sexual Function in Female Patients with Rheumatoid Arthritis: A 6 Month Follow-Up Study
Abstract Poster Presenter: Daniel Zavada, MD – Charles University, Third Faculty of Medicine
10:30 AM - 12:30 PM Central Time

Measuring Rheumatoid Arthritis Outcomes Using Machine Learning Imputed Disease Activity Scores
Abstract Poster Presenter: Jue Hou, PhD – University of Minnesota
10:30 AM - 12:30 PM Central Time

Molecular Signature Response Classifier Identifies Contribution of GLP-1 Therapy to TNF Inhibitor Response in Rheumatoid Arthritis Patients
Abstract Poster Presenter: Ryan Phan, PhD (he/him/his) – Scipher Medicine
10:30 AM - 12:30 PM Central Time

Multimodal Spatial and Single-Cell Profiling of Synovial Tissue Reveals Macrophage Programs Associated with Biologic TherapyTreatment Response in Rheumatoid Arthritis
Abstract Poster Presenter: Mohammad Daud Khan, MS – Northwestern University
10:30 AM - 12:30 PM Central Time

Phase 3 Study of the Efficacy, Safety and Immunogenicity of the Proposed Tocilizumab Biosimilar RGB-19, Intravenously Administered to Participants With Active Rheumatoid Arthritis: 52-Week Data
Abstract Poster Presenter: Gerd Burmester, MD – Charité - Universitätsmedizin Berlin
10:30 AM - 12:30 PM Central Time

Prediction of 5-Year Fracture Risk in Rheumatoid and Psoriatic Arthritis Using REMS Technology
Abstract Poster Presenter: Edmund MacLaughlin, MD – Rheumatology Associates of Delmarva
10:30 AM - 12:30 PM Central Time

Real World Evaluation on the Effectiveness of Baricitinib or Other Treatments in Patients With Rheumatoid Arthritis: Data from the European and Non-European Cohorts of the RA-BE-REAL Study
Abstract Poster Presenter: AJ Fernandez, n/a – Eli Lilly and Company
10:30 AM - 12:30 PM Central Time

Real-World Evidence for the Superiority of Subcutaneous Methotrexate in RA: A Comparative Observational Study with Ultrasonographic Assessment
Abstract Poster Presenter: Masatsugu Komagamine, MD, PhD – Iwate Medical University hospital
10:30 AM - 12:30 PM Central Time

The Better Disease-modifying antirheumatic drug (DMARD)? Efficacy and Safety of Methotrexate Versus Leflunomide Monotherapy in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Abstract Poster Presenter: Aakanksha Pitliya, MD (she/her/hers) – Mercy Catholic Medical Center, Darby, PA
10:30 AM - 12:30 PM Central Time

Thrombocytosis Predicts Response to Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis: Data from the Korean KOBIO Registry
Abstract Poster Presenter: Sehee Kim, MD, PhD – Kyunghee university at Gangdong
10:30 AM - 12:30 PM Central Time

Treatment Patterns and Outcomes After Janus Kinase Inhibitor Discontinuation in Rheumatoid Arthritis: A Real-World Cohort Study
Abstract Poster Presenter: Sungwon Ko, MD – ASAN MEDICAL CENTER
10:30 AM - 12:30 PM Central Time

Use of (MSB11456), the first tocilizumab biosimilar approved for rheumatoid arthritis: 6-month data from an international observational study
Abstract Poster Presenter: Jonathan Kay, MD – UMass Chan Medical School
10:30 AM - 12:30 PM Central Time

Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance ofbeing off steroids and escalation of therapy at 1 year
Abstract Poster Presenter: Janet Pope, MD, FRCPC, MPH – University of Western Ontario